EXPLORING THE POTENTIAL BUDGET IMPACT OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

被引：0
|
作者：
Cortesi, P. A. [1 ]
D'Angiolella, L. S. [1 ]
Ferrario, M. [2 ]
Cesana, G. [1 ]
Mantovani, L. G. [1 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Roche SpA, Monza, Italy
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2619
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY42
引用
收藏
页码：S442 / S443
页数：3
相关论文
共 50 条
  • [21] Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National US Survey
    Al-Samkari, Hanny
    Croteau, Stacy E.
    [J]. BLOOD, 2019, 134
  • [22] IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA
    Moreno, N. A.
    Munoz-Bedoya, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [23] Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor
    Nakajima, Yuto
    Tonegawa, Hitoshi
    Noguchi-Sasaki, Mariko
    Nogami, Keiji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 789 - 796
  • [24] Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor
    Yuto Nakajima
    Hitoshi Tonegawa
    Mariko Noguchi-Sasaki
    Keiji Nogami
    [J]. International Journal of Hematology, 2021, 113 : 789 - 796
  • [25] Inhibitor status of patients with Hemophilia A who transition to Emicizumab after Immune Tolerance Induction
    Batsuli, Glaivy
    Greene, Amanda
    Meeks, Shannon L.
    Sidonio, Robert F., Jr.
    [J]. HAEMOPHILIA, 2020, 26 : 28 - 28
  • [26] COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY
    Guler, B.
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    [J]. VALUE IN HEALTH, 2019, 22 : S851 - S851
  • [27] Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
    Ahn, Ji Hyun
    Jung, Nani
    Shim, Ye Jee
    Kim, Heung Sik
    [J]. BLOOD RESEARCH, 2021, 56 (01) : 44 - 46
  • [28] Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Shimonishi, Naruto
    Furukawa, Shoko
    Yada, Koji
    Ogiwara, Kenichi
    Takeyama, Masahiro
    Shima, Midori
    Nogami, Keiji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (04) : 489 - 498
  • [29] Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients
    Yuto Nakajima
    Kuniyoshi Mizumachi
    Naruto Shimonishi
    Shoko Furukawa
    Koji Yada
    Kenichi Ogiwara
    Masahiro Takeyama
    Midori Shima
    Keiji Nogami
    [J]. International Journal of Hematology, 2022, 115 : 489 - 498
  • [30] BUDGET IMPACT OF MAKING EMICIZUMAB AVAILABLE AT THE COMMUNITY PHARMACY IN ADDITION TO THE HOSPITAL PHARMACY
    Leleu, H.
    Fraticelli, L.
    Roula, A.
    Le Lay, K.
    de Lehvenfehlt, A.
    Bergougnoux, L.
    Chamouard, V
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S97 - S97
12345